Moberg Pharma AB (publ)
SSE:MOB.ST
15.1 (SEK) • At close February 20, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Moberg Pharma AB (publ) |
Symbool | MOB.ST |
Munteenheid | SEK |
Prijs | 15.1 |
Beurswaarde | 422,219,043 |
Dividendpercentage | 0% |
52-weken bereik | 4.133 - 22.8 |
Industrie | Drug Manufacturers—Specialty & Generic |
Sector | Healthcare |
CEO | Ms. Kerstin Valinder Strinnholm |
Website | https://www.mobergpharma.se |
An error occurred while fetching data.
Over Moberg Pharma AB (publ)
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products in Europe, the United States, and internationally. It develops MOB-015, which has completed Phase III clinical trial for the treatment of nail fungus. The company was formerly known as Moberg Derma AB (publ) and changed its name to
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (SEK)
Cijfers zijn in miljoenen (SEK)